The Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies.

Published Date: 04 May 2023

The sensitivity rates for the -synuclein skin biopsy test developed by CND Life Sciences ranged from 92.7% to 100% for a variety of synucleinopathies that were evaluated and clinically confirmed, including Parkinson disease and dementia with Lewy bodies, among others.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

Glioblastoma treatment breakthrough shows promise

3.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

4.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot